PHARMACEUTICAL COMPOSITION

The present invention provides a pharmaceutical composition comprising: a multi-branched copolymer comprising at least three polyester arms, wherein the polyester is poly(ε-caprolactone-co-lactic acid), attached to a central core which comprises a polyether, and wherein the multi-branched copolymer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LOPEZ NORIEGA, Adolfo, NICOULIN, Victor, CAGNON, Marie-Emérentienne, CROS, Jean-Manuel, NG, Feifei, SERINDOUX, Juliette, CURIA, Silvio
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY COMPOSITIONS BASED THEREON COMPOSITIONS OF MACROMOLECULAR COMPOUNDS HUMAN NECESSITIES HYGIENE MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONSONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC MACROMOLECULAR COMPOUNDS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES THEIR PREPARATION OR CHEMICAL WORKING-UP
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides a pharmaceutical composition comprising: a multi-branched copolymer comprising at least three polyester arms, wherein the polyester is poly(ε-caprolactone-co-lactic acid), attached to a central core which comprises a polyether, and wherein the multi-branched copolymer is substantially insoluble in aqueous solution, further comprising at least one pharmaceutically active ingredient, and a pharmaceutically acceptable organic solvent in an amount of at least 20% (w/w%) of the total composition. La présente invention concerne une composition pharmaceutique comprenant : un copolymère multiramifié comprenant au moins trois bras de polyester, le polyester étant l'acide poly(ε-caprolactone-co-lactique), fixé à un noyau central qui comprend un polyéther, et le copolymère multiramifié étant sensiblement insoluble dans une solution aqueuse, comprenant en outre au moins un ingrédient pharmaceutiquement actif, et un solvant organique pharmaceutiquement acceptable en une quantité d'au moins 20 % (% p/p) de la composition totale.